Health
GSK’s Shingles Shot Linked to Delayed Dementia Onset in Study
- Findings need follow-up to establish protective mechanism
- Impact appears similar to new Alzheimer’s drugs: researcher
A scientist works in a GSK laboratory in Stevenage, UK.
Photographer: Vivian Wan/BloombergThis article is for subscribers only.
GSK Plc’s shingles vaccine was linked to a longer delay in dementia onset than a competing shot, a finding that suggests superior protective powers against one of the world’s most threatening conditions.
People who received the Shingrix vaccine lived an average of 164 days longer without a dementia diagnosis than those who got Merck & Co.’s Zostavax, according to a study published Thursday in the Nature Medicine journal. The Merck vaccine was linked to lower dementia risk in a study last year.